Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00107393
First received: April 5, 2005
Last updated: July 9, 2013
Last verified: October 2006

April 5, 2005
July 9, 2013
June 2003
May 2008   (final data collection date for primary outcome measure)
Median survival and 2-year survival rate as measured by the Kaplan-Meier method 2 years after completion of study treatment [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00107393 on ClinicalTrials.gov Archive Site
  • Progression-free survival [ Designated as safety issue: No ]
  • Response rate [ Designated as safety issue: No ]
  • Clinical benefit rate as measured by Kaplan-Meier method 2 years after completion of study treatment [ Designated as safety issue: No ]
  • Safety profile as measured by the Kaplan-Meier method 2 years after completion of study treatment [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer
Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with capecitabine may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving trastuzumab together with capecitabine works in treating women with metastatic breast cancer.

OBJECTIVES:

Primary

  • Determine the median survival time and 2-year survival rate in women with taxane- and anthracycline-refractory HER2/neu-overexpressing metastatic breast cancer treated with trastuzumab (Herceptin®) and capecitabine.

Secondary

  • Determine the progression-free survival of patients treated with this regimen.
  • Determine the response rate in patients treated with this regimen.
  • Determine the clinical benefit rate of this regimen in these patients.
  • Determine the safety profile of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to prior treatment with trastuzumab (Herceptin®) (yes vs no), HER2/neu status (3+ by immunohistochemistry vs positive by fluorescence in situ hybridization), and class of refractory disease (primary vs secondary vs treatment discontinuation due to adverse events).

Patients receive oral capecitabine once daily on days 1-21 and trastuzumab IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for up to 2 years.

PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study within 3 years.

Interventional
Phase 2
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Biological: trastuzumab
  • Drug: capecitabine
Not Provided
Ishida T, Kiba T, Takeda M, Matsuyama K, Teramukai S, Ishiwata R, Masuda N, Takatsuka Y, Noguchi S, Ishioka C, Fukushima M, Ohuchi N. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol. 2009 Jul;64(2):361-9. Epub 2008 Dec 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
75
November 2008
May 2008   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed breast cancer

    • Metastatic disease

      • Patients with only bone metastases are not eligible
  • Refractory disease, defined as disease progression, drug-related adverse reaction, or disease relapse during or within 12 months after completion of paclitaxel or docetaxel AND doxorubicin or epirubicin administered in the neoadjuvant, adjuvant, or metastatic setting

    • Total neoadjuvant or adjuvant taxane dose > 700 mg/m^2 for paclitaxel or > 240 mg/m^2 for docetaxel
    • Total taxane dose > 350 mg/m^2 for paclitaxel or > 120 mg/m^2 for docetaxel in the metastatic setting
    • Total neoadjuvant or adjuvant anthracycline dose > 240 mg/m^2 for doxorubicin or epirubicin
    • Total anthracycline dose > 120 mg/m^2 for doxorubicin or epirubicin in the metastatic setting
  • HER2/neu overexpression

    • 3+ by immunohistochemistry or positive by fluorescence in situ hybridization
  • No symptomatic brain metastases
  • No pleural or pericardial effusion or ascites
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 20 to 75

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • ECOG 0-2

Life expectancy

  • At least 3 months

Hematopoietic

  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL

Hepatic

  • SGOT or SGPT ≤ 2.0 times upper limit of normal (ULN) (< 3.0 times ULN for patients with liver metastases)
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Bilirubin ≤ 1.5 mg/dL

Renal

  • Creatinine ≤ 1.2 mg/dL

Cardiovascular

  • LVEF > 50%

Pulmonary

  • No interstitial pneumonia with pulmonary fibrosis

Other

  • No history of hypersensitivity reactions
  • No serious, uncontrolled infection
  • No other malignancy
  • Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Prior trastuzumab (Herceptin®) for metastatic disease allowed

Chemotherapy

  • See Disease Characteristics
  • No prior capecitabine
  • At least 2 weeks since prior antimetabolites for metastatic disease
  • At least 4 weeks since prior alkylating agents, carcinostatic antibiotics, or other carcinostatic agents

Endocrine therapy

  • At least 4 weeks since prior goserelin or leuprolide for metastatic disease
  • At least 2 weeks since prior oral endocrine agents for metastatic disease
  • No concurrent endocrine therapy

Radiotherapy

  • No prior radiotherapy to target lesions
  • At least 4 weeks since prior radiotherapy
  • No concurrent radiotherapy, including radiotherapy for brain metastases

Surgery

  • Not specified

Other

  • Concurrent bisphosphonates for bone metastases allowed
Female
20 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00107393
TUGSM-UHA-BC03-01, CDR0000380787
Not Provided
Not Provided
Tohoku University
Not Provided
Study Chair: Noriaki Ohuchi, MD Tohoku University
National Cancer Institute (NCI)
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP